Early triple-negative breast cancer (TNBC) represents a challenging breast cancer subtype due to its aggressive nature and lack of hormone receptors or HER2 overexpression, which excludes targeted therapies like endocrine therapy or HER2-targeted agents. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.